Lario Therapeutics Secures $6 Million Grant for Parkinson’s Disease Research
Lario Therapeutics secures $6 million funding from The Michael J. Fox Foundation to advance research on Parkinson’s disease. This grant will support the company’s preclinical program focused on CaV2.3 calcium channel inhibition, aiming to develop innovative treatments for millions affected by this neurodegenerative disorder.
Ovid Therapeutics Expands Scientific Advisory Board to Enhance Neurology Research
Ovid Therapeutics Inc. has expanded its Scientific Advisory Board with leading neurologists and neuroscientists to enhance its innovative pipeline for treating rare epilepsies and brain disorders. The board, chaired by Professor Robert Langer, aims to advance research on compounds targeting ROCK2 inhibition and KCC2 activation, potentially transforming treatment for complex neurological conditions.
World Brain Day 2024 to Focus on ‘Brain Health and Prevention’
Join the World Federation of Neurology on July 22, 2024, for the 11th annual World Brain Day, themed ‘Brain Health and Prevention.’ This global initiative aims to unite neurologists, patients, and advocates to address neurological disease risk factors and promote early detection. Participate in a free public webinar featuring experts from WHO and the World Stroke Organization. Learn about preventive measures and the importance of brain health in combating neurological disorders affecting billions worldwide.
New Migraine Treatment Atogepant Shows Promise in Reducing Symptoms and Medication Dependence
Recent advancements in migraine treatment highlight atogepant, a CGRP inhibitor, which has shown significant promise in reducing migraine days and reliance on pain medications. A phase 3 trial published in Neurology demonstrated its effectiveness in chronic migraine patients, offering hope for improved quality of life and innovative solutions for migraine management.
Potential Breakthrough in PSP Diagnosis
Researchers at the University of California, San Francisco have identified a pattern in the spinal fluid of Progressive Supranuclear Palsy (PSP) patients, offering hope for a diagnostic test and targeted therapies. Early diagnosis is crucial as PSP progresses rapidly and current treatments are ineffective. Utilizing high-throughput technology for protein analysis, the study may revolutionize PSP diagnosis and treatment.
Study Finds Genetic Risk of Alzheimer’s Disease More Influenced by Mother’s Side
A recent study published in JAMA Neurology reveals that the genetic risk of developing Alzheimer’s disease is more influenced by the mother’s side than the father’s side. With the prevalence of dementia expected to nearly double every 20 years, these insights could lead to improved methods of diagnosis, treatment, and prevention. The study, analyzing data from over 4,000 individuals, emphasizes the importance of understanding familial influences on Alzheimer’s risk for developing targeted interventions and treatments.
Study Reveals Alarming Increase in Mortality Rates from Neurological Diseases in Young Adults
A recent preprint study by Phinance Technologies reveals a concerning increase in mortality rates among individuals under 44 due to neurological diseases. The study highlights a significant rise in deaths linked to conditions like Guillain-Barré syndrome and acute disseminated encephalomyelitis, signaling a departure from historical trends. This alarming trend underscores the need for further investigation and proactive measures to address this growing public health concern.
MIT Engineers Develop Implantable Ultrasound Device for Neurological Disorders
MIT engineers have developed the ImPULS device, an implantable ultrasound technology that could revolutionize the treatment of neurological disorders like Parkinson’s disease. This groundbreaking device offers a minimally invasive alternative to traditional deep brain stimulation, potentially reducing tissue damage and increasing treatment efficacy. The device, as thin as a human hair, uses ultrasound instead of electricity for deep brain stimulation, showing promising results in triggering dopamine release. This innovation not only has therapeutic applications but also holds promise for advancing neuroscience research.
Groundbreaking Discovery in Parkinson’s Disease Research
Groundbreaking research on Parkinson’s disease reveals potential FDA-approved treatment targeting cell surface protein Aplp1 and Lag3 to block spread of harmful material. Findings suggest promising therapy avenue already available, offering hope to millions worldwide.
Smartwatches and Mobile Phones Revolutionize Parkinson’s Disease Research
University of Rochester Medical Center researchers have utilized smartwatches and mobile phones to track Parkinson’s disease progression in its early stages, showcasing the potential of everyday consumer devices in understanding neurological disorders. The WATCH-PD study, supported by the Michael J. Fox Foundation, has extended its research to engage pharmaceutical companies and industry regulators in exploring the effectiveness of smart devices in monitoring Parkinson’s disease.